MedTrace Logo

Assessment of Vulnerability to Carotid Stenosis by MultiModal Imaging and Cellular and Molecular Biology Analysis

NCT05190510 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2024-07-30

No results posted yet for this study

Summary

Cerebrovascular accidents (CVA) are the second leading cause of death in France, and the most frequent cause of acquired physical and mental disability. Up to 90% of strokes are ischemic, among which about 15% are due to the presence of stenosis of the carotid sinus, at the base of the extracranial internal carotid artery.

For many years, only the degree of stenosis was used to assess the risk of stroke, based on the results of original studies from the 1990s. However, the significant improvement in medical treatments since then has significantly reduced the risk of stroke, and the benefits of carotid intervention are becoming increasingly debatable.

Since the publication of the latest recommendations, the degree of stenosis alone is no longer sufficient to propose an intervention, since most of them will never lead to a neurological event. In addition to stenosis greater than 60%, for the first time, other criteria must be sought to decide on treatment. For example, so-called carotid plaque "vulnerability" criteria, defining patients "at high risk of stroke," should be sought.

Conditions

  • Internal Carotid Artery
  • Atheromatous Stenosis

Interventions

OTHER

Data collection

Collection of data from preoperative imaging examinations (routine examination prescribed before the operation)

PROCEDURE

collection of the carotid plaque (surgical specimen)

collection of the carotid plaque

OTHER

anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens

anatomopathological, histological, cellular and molecular biology examinations (metabolomics and transcriptomics) on surgical specimens

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Dijon

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-14
Primary Completion
2023-01-26
Completion
2023-01-26

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05190510 on ClinicalTrials.gov